Payment overview · 2025
General Payments
$120.86
7 reported records · 5 companies
Healthcare provider profile · identity verified
Charles Noble, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDRIA, IN · NPI 1881755775
Verified facts
What the public records show
CMS Open Payments records show Charles Noble, MD received $120.86 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.99 | 28.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.68 | 24.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.02 | 19.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.03 | 15.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.14 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.86 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 16 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 205 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
205 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 954 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 618 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 144 |
| Omeprazole | Omeprazole | 398 | 116 |
| Losartan Potassium | Losartan Potassium | 393 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 346 | 81 |
| Lisinopril | Lisinopril | 342 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 93 |
| Gabapentin | Gabapentin | 289 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 91 |
| Metformin Hcl | Metformin Hcl | 267 | 79 |
| Ozempic | Semaglutide | 205 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 203 | 47 |
| Jardiance | Empagliflozin | 200 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 54 |
| Furosemide | Furosemide | 164 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 38 |
| Simvastatin | Simvastatin | 143 | 39 |
| Trazodone Hcl | Trazodone Hcl | 142 | 31 |
| Alendronate Sodium | Alendronate Sodium | 141 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 35 |
| Metformin Hcl Er | Metformin Hcl | 136 | 41 |
| Alprazolam | Alprazolam | 134 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 32 |
| Tramadol Hcl | Tramadol Hcl | 120 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 44 |
| Meloxicam | Meloxicam | 113 | 27 |
| Montelukast Sodium | Montelukast Sodium | 110 | 27 |
| Allopurinol | Allopurinol | 108 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 30 |
| Glimepiride | Glimepiride | 98 | 27 |
| Eliquis | Apixaban | 94 | 25 |
| Carvedilol | Carvedilol | 86 | 29 |
| Atenolol | Atenolol | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 23 |
| Sertraline Hcl | Sertraline Hcl | 79 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 21 |
| Januvia | Sitagliptin Phosphate | 75 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 15 |
| Lorazepam | Lorazepam | 70 | 12 |
| Clonazepam | Clonazepam | 68 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 56 |
| Meclizine Hcl | Meclizine Hcl | 60 | 19 |
| Prednisone | Prednisone | 58 | 34 |
| Glipizide Er | Glipizide | 57 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 13 |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 52 | 13 |
| Clonidine Hcl | Clonidine Hcl | 51 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 11 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 13 |
| Spironolactone | Spironolactone | 47 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 15 |
| Trulicity | Dulaglutide | 45 | 11 |
| Pregabalin | Pregabalin | 44 | 15 |
| Torsemide | Torsemide | 44 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Estradiol | Estradiol | 41 | 11 |
| Famotidine | Famotidine | 38 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 16 |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Nystatin | Nystatin | 29 | 15 |
| Ramipril | Ramipril | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Linzess | Linaclotide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 15 |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Azithromycin | Azithromycin | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.86 · 7 records | PFIZER INC. | ABRYSVO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, TRINTELLIX, UBRELVY, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error